Abgenix, Inc.

Overview

Abgenix, Inc. was a biotechnology company that specialized in the development of monoclonal antibody-based therapies for the treatment of serious medical conditions such as cancer. Abgenix harnessed the power of transgenic mice technology to create fully human antibodies. In 2005, it was acquired by Amgen Inc.

Therapeutic areas

API / Drug Master Files

Abgenix, Inc. holds 0 active (3 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• BULK PURIFIED MURINE MONOCLONAL ANTIBODY (ABX-CBL) TO BLAST CELLSInactive1999-06-04
• HUMAN MONOCLONAL ANTIBODY (ABX-EGF) TO EPIDERMAL GROWTH FACTOR RECEPTORInactive1999-05-15
• BULK PURIFIED HUMAN MONOCLONAL ANTIBODY (ANTI-IL8) (NSO CELLS, LONZA) TO IL-8Inactive1997-12-30

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Abgenix, Inc. in our records. PharmaTek screens the full directory against live FDA enforcement data.